FC
PTCT icon

Financial Consulate’s PTC Therapeutics PTCT Stock Holding History

Financial Consulate’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$408 Hold
5
– – ﹤0.01% 1371
2026
Q1 		$341 Hold
5
– – ﹤0.01% 1325
2025
Q4 		$380 Hold
5
– – ﹤0.01% 1249
2025
Q3 		$307 Buy
+5
New +$260 ﹤0.01% 1111

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Financial Consulate's PTCT Position: Q2 2026 in Review

Financial Consulate held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 5 shares worth $408. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

Financial Consulate first reported a position in PTCT in Q3 2025 and has held it in 4 quarters since. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Financial Consulate held 5 shares of PTC Therapeutics worth $408 as of Q2 2026.
  • Financial Consulate left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #1371 holding.
  • Financial Consulate first reported a position in PTC Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.